北京博星证券投资顾问有限公司 关于江苏康众数字医疗科技股份有限公司 2026 年股票期权激励计划 首次授予事项的 | 目 录 | 1 | | --- | --- | | 释 义 | 2 | | 声 明 | 3 | | 一、本激励计划已履行的必要程序 | 4 | | 二、本激励计划首次授予事项 | 5 | | 三、本激励计划授予条件成就说明 | 8 | | 四、结论性意见 | 9 | | 五、备查信息 10 | | 释 义 除非上下文文意另有所指，下列词语具有如下含义： | 康众医疗、上市公司、公司 | 指 | 江苏康众数字医疗科技股份有限公司（证券简称：康众 | | --- | --- | --- | | | | 医疗；证券代码：688607） | | 股权激励计划、股票期权激 | 指 | 江苏康众数字医疗科技股份有限公司 2026 年股票期权 | | 励计划、本激励计划 | | 激励计划 | | 《股权激励计划（草案）》 | 指 | 《江苏康众数字医疗科技股份有限公司 年股票期 2026 | | | | 权激励计划（草案）》 | | 独立财务顾问报告、本报告 | 指 | 《北京博星证券投资顾问有限公司关于江 ...

江苏康众数字医疗科技股份有限公司 综上，本激励计划首次授予激励对象的主体资格合法、有效。 江苏康众数字医疗科技股份有限公司 董事会薪酬与考核委员会 2026 年 2 月 12 日 董事会薪酬与考核委员会关于 2026 年股票期权激励计划 首次授予激励对象名单的核查意见 江苏康众数字医疗科技股份有限公司（以下简称"公司"）董事会薪酬与考 核委员会依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股 权激励管理办法》《上海证券交易所科创板股票上市规则》《科创板上市公司自律 监管指南第 4 号—股权激励信息披露》《公司章程》等有关规定，对 2026 年股票 期权激励计划（以下简称"本激励计划"）首次授予激励对象名单发表核查意见 如下： （一）本激励计划首次授予激励对象符合《中华人民共和国公司法》《中华 人民共和国证券法》《公司章程》规定的任职资格；符合《上海证券交易所科创 板股票上市规则》规定的激励对象条件，包括：1、不存在最近 12 个月内被证券 交易所认定为不适当人选的情形；2、不存在最近 12 个月内被中国证监会及其派 出机构认定为不适当人选的情形；3、不存在最近 12 个月内因重大违法违规行为 ...

经济观察网康众医疗近期推进股票期权激励计划，并增资AI医疗影像公司脉得智能。公司2025年业绩 预告显示净利润亏损。 高管变动 公司于2026年1月27日召开临时股东会，审议通过了《2026年股票期权激励计划(草案)》及相关考核办 法。该计划旨在调动核心团队积极性，后续实施细节(如授予条件、行权安排等)可能成为关注点。 2026年2月6日，康众医疗公告拟使用自有资金7000万元增资脉得智能科技(无锡)有限公司，持股比例达 7.3684%。此举旨在切入AI医疗影像领域，投资后的业务整合、技术协同及业绩贡献可能在未来逐步显 现。 业绩经营情况 公司已发布业绩预告，预计2025年全年归属净利润亏损500万至900万元，扣非净利润亏损1200万至1800 万元。正式年报预计将在后续发布，届时可关注详细财务数据及业绩说明。 以上内容基于公开资料整理，不构成投资建议。 公司项目推进 ...

2月11日，康众医疗跌2.23%，截至发稿，报52.55元/股，成交8840.27万元，换手率1.89%，总市值46.31 亿元。康众医疗股价已经连续6天下跌，区间累计跌幅12.95%。 资料显示，江苏康众数字医疗科技股份有限公司位于江苏省苏州工业园区星湖街218号生物纳米园A2 楼,B3楼501室，成立日期2007年5月23日，上市日期2021年2月1日，公司主营业务涉及数字化X射线平 板探测器研发、生产、销售和服务。主营业务收入构成为：平板探测器销售96.41%，配件销售及维修 3.59%。 从基金十大重仓股角度 数据显示，华西基金旗下1只基金重仓康众医疗。华西研究精选混合发起A（020444）四季度持有股数 2.35万股，占基金净值比例为3.18%，位居第十大重仓股。根据测算，今日浮亏损失约2.82万元。连续6 天下跌期间浮亏损失18.37万元。 华西研究精选混合发起A（020444）成立日期2023年12月28日，最新规模3144.17万。今年以来收益 12.28%，同类排名874/8884；近一年收益6.56%，同类排名6848/8127；成立以来收益11.4%。 华西研究精选混合发起A（02044 ...

Group 1 - The core viewpoint of the article highlights the rapid growth and potential of the Ultra-Wideband (UWB) technology market in China, with projections indicating that the market value will exceed 10 billion yuan by 2026 and reach around 20 billion yuan by 2028 [2] - UWB technology is characterized by its nanosecond-level narrow pulse wireless communication capabilities, offering centimeter-level positioning accuracy, high-speed data transmission, low power consumption, and strong anti-interference abilities, making it suitable for various applications such as indoor positioning, smart transportation, IoT, and radar detection [2] - The company has developed multiple UWB products with promising market prospects and is collaborating with invested enterprises to advance the research and development of UWB-related products, with steady progress in market promotion expected to contribute to the company's revenue by 2026 [2]

此次对外投资旨在推进公司多元化战略布局，把握AI医疗影像行业的结构性机遇，切入精准医疗前沿领域。 （康众医疗公告） 脉得智能在2025年度的营业收入为5161万元，归母净利润约亏损2587万元。公司表示，投资后将有助于加快产品研 发、市场渠道建设与临床维护的进程，期望释放业绩增长潜力。 近日，康众医疗发布公告称，公司拟使用自有资金7000万元人民币以增资形式参股脉得智能科技（无锡）有限公司， 新增注册资本103万元。增资完成后，公司持有脉得智能7.3684%的股权。 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [2][33]. Core Insights - The pharmaceutical sector saw a slight increase of 0.14% in the week, while the Shanghai Composite Index decreased by 1.27% [3][2]. - The report highlights the implementation of the "Traditional Chinese Medicine Industry High-Quality Development Implementation Plan (2026-2030)" by the Ministry of Industry and Information Technology and other departments, aiming to enhance the supply chain and technological advancements in the traditional Chinese medicine sector [11][12]. - Key pharmaceutical products such as Eli Lilly's Tirzepatide are projected to generate significant sales, with estimates of $36.5 billion in 2025, reflecting a 99% year-on-year growth for the diabetes version and a 175% growth for the weight loss version [15][17]. - The report notes active licensing and collaboration in the industry, with significant deals such as a $1.5 billion agreement between Saint's RNAi therapy and Genentech, and various other collaborations involving companies like Jichuan Pharmaceutical and Baiyunguan [18][20]. Market Performance Summary - The overall valuation of the pharmaceutical sector is reported at 29.6 times earnings, ranking 13th among 31 sectors [4][14]. - The performance of various sub-sectors includes: - Raw materials (+0.6%) - Traditional Chinese Medicine (+2.6%) - Chemical preparations (-0.8%) - Medical devices (+0.1%) [4][3]. Key Events and Developments - The report emphasizes the importance of the new plan for traditional Chinese medicine, which includes goals such as establishing 60 high-standard raw material production bases and developing 10 major traditional Chinese medicine products by 2030 [12][11]. - Notable company developments include: - Eli Lilly's projected revenue growth driven by Tirzepatide [15]. - And the announcement of significant profit forecasts from Heptares Pharmaceuticals, indicating a shift towards profitability [16]. Investment Recommendations - The report suggests focusing on domestic companies related to traditional Chinese medicine, such as Zoli Pharmaceutical and Yunnan Baiyao, as well as innovative drug companies like Heng Rui Pharmaceutical and Bai Jie Shen Zhou [2][18].

Core Viewpoint - The company is investing 70 million RMB to acquire a 7.3684% stake in Pide Intelligent, aiming to enhance its diversified strategic layout and capitalize on structural opportunities in the AI medical imaging industry [1][2]. Group 1: Investment Rationale - The AI medical industry is experiencing rapid growth, with clear market potential and supportive national policies facilitating the implementation of AI in medical imaging and ultrasound quality control [2]. - Pide Intelligent has developed unique competitive advantages in the AI medical sector, particularly in ultrasound AI, and the investment will accelerate product development and market expansion [2]. - This investment represents a proactive attempt by the company to diversify its strategic layout and cultivate new economic growth points while maintaining stable development in its core business of X-ray flat panel detectors [2]. Group 2: Strategic Benefits - The investment is expected to optimize asset allocation and mitigate risks associated with single industry cycles by entering the high-growth ultrasound AI field [2]. - The underlying technologies of Pide Intelligent, such as image recognition, big data analysis, and AI algorithms, have commonalities with high-end equipment manufacturing and IT services, allowing the company to leverage strategic and business synergies [2]. - Successful resource integration and business expansion could open new growth avenues for the company, positively impacting its operational development [3].

Core Viewpoint - The company plans to invest 70 million yuan in a capital increase to acquire a 7.3684% stake in Maide Intelligent Technology (Wuxi) Co., Ltd, aiming to enhance its diversified strategic layout and seize opportunities in the AI medical imaging industry [1] Group 1 - The investment will increase the registered capital of Maide Intelligent by 1.03457674 million yuan [1] - The move is part of the company's strategy to tap into the frontier of precision medicine and cultivate new performance growth points [1]

Core Viewpoint - The company plans to invest 70 million yuan in a capital increase to acquire a 7.3684% stake in Maide Intelligent Technology (Wuxi) Co., Ltd, aiming to enhance its diversified strategic layout and seize opportunities in the AI medical imaging industry [1] Group 1 - The investment will increase the registered capital of Maide Intelligent by 1.03457674 million yuan [1] - The move is part of the company's strategy to tap into the frontier of precision medicine and cultivate new performance growth points [1]